Bronchiectasis
Conditions
Keywords
CSLD, Child, Nebuliser, Hypertonic Saline, Outcome, Chronic cough
Brief summary
To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD. Secondary Aims: To determine the: 1. Efficacy of nebulized 5% hypertonic saline on airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics. 2. Efficacy of nebulized 5% hypertonic saline on lung function 3. Adverse effects of nebulized 5% hypertonic saline in children
Detailed description
Primary Aim: To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD. Here the investigators will be using validated pediatric cough questionnaires to asses this. Patients will answer these questionnaires at first recruitment ( -1 mth), at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths) Secondary Aims: To determine the: 1. Efficacy of nebulized 5% hypertonic saline on the airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics. Here the investigators will be taking history on the exacerbations, use of antibiotics and healthcare utilization before and after use of the hypertonic saline. Furthermore, Nasopharyngeal swabs will be done to review possible changes in microbiota, again before and after use of the 5% HS. 2. Efficacy of nebulized 5% hypertonic saline on lung function. Here is investigators will be doing portable spirometry ( pre and post bronchodilator). Patients will perform at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths) 3. Adverse effects of nebulized 5% hypertonic saline in children HS has been associated with side-effects. The investigators will monitor this. We will asses presence of these symptoms at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths) to ensure these are from the nebulizer.
Interventions
DRUGNebulized 5% Hypertonic saline
nebulized 0.9% saline
Sponsors
University of Malaya
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double-blind
Intervention model description
Double-blind Placebo-controlled trial
Eligibility
Sex/Gender
ALL
Age
3 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients \< 18 years old * Followed up in the paediatric respiratory clinic of UMMC with a diagnosis of CSLD
Exclusion criteria
* Incomplete data or refusal to participate * Unwell and/or unable to stop HS and/or antibiotics of any preparation other than azithromycin ( EOD * On supplementary oxygen/home ventilation * Poorly controlled asthma (as in the GINA guidelines) or bronchoconstriction that precedes the use of hypertonic saline. * Oral antibiotics for less than 4 weeks before randomization for medication. * Fall in PEFR \> 20% post 5% HS challenge test or a positive HS challenge test in young children, as mentioned below.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the Short Parent-proxy cough quality of life (PC-QOL) score | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | Short PCQOL: This is a validated cough quality-of-life(QoL) questionnaire for parents of children with chronic cough, with a translated Malay version. Minimal Important Difference(MID) of 0.9 has been found in the validation study. The answers are on a Likert scale from 1 (every time) to 7( none). A lower score denotes a lower quality of life. The patients will answer either the English or the translated Malay version |
| Change in the Chronic Cough-specific QoL(CC-QOL) score | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | Chronic cough-specific QOL: This is a validated cough QoL questionnaire to be answered by children 7 years till 18 years old with a MID of about 1.1. The answers are in a Likert scale from 1 ( every time) to 7( none). A lower score denotes a lower quality of life. The patients will answer either the English or the translated Malay version |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Unscheduled Health Care Visits | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | any unscheduled doctor visits for cough, shortness of breath or any other respiratory associated symptom. This will be for the last 3 months before day 1 of randomization and after 3 months of use of study drug |
| No of episodes of rescue antibiotics | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | Prescription of antibiotics (including nebulized antibiotics) at least for 3 days for respiratory associated symptoms. This will be in the past 3 months, before randomization and during the next 3 months, while on the study drug. |
| FEV1 | At day 1 of randomization, at 3 months of use of study drug | FEV1 will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEV1 value will be converted into z-score by using GrowingLungs software. |
| FVC | At day 1 of randomization, at 3 months of use of study drug | FVC will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FVC value will be converted into z-score by using GrowingLungs software. |
| Airway microbiome | At day 1 of randomization, at 3 months of use of study drug | DNA will be extracted from swabs using the Qiagen DNA Isolation Kit in accordance with the manufacturer's instructions. Bacterial profiling utilised the 16S rRNA gene targeting variable regions V3 - V4 will be carried out using Nextseq 2500 platform. Resulting raw fastq data will be processed using Dada2 R package and exported into phyloseq Rprogram for downstream analysis. The Alpha diversity will be measured using the Shannon and Simpson diversity indices while the beta diversity will be accessed using principle coordinate analysis and Permutational multivariate analysis of variance(PERMANOVA). Differentially abundant taxa will be identified by comparing the fold-change different using DESeq2. |
| PEFR ( pre and post), if possible | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | The best PEFR measure out of 3 reproducible attempts ( both pre and post 4 puffs of MDI Salbutamol), performed when relatively well and stable, will be recorded for analysis. |
| Cough diary | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | The cough score will be assessed using the Malay version, used in the HOspitalised Pneumonia Extended study, whereby the cough score will be tabulated daily. The cough diary has recordings for both day time cough: score 0 ( no cough) till score 5 ( Cannot perform most usual day-time activity due to severe coughing). The night cough is scored score 0 ( no cough) till score 5 ( distressing cough.). A higher score indicates more severe cough. |
| Number of Adverse events | At day 1 of randomization, at 3 months of use of study drug | cough, haemoptysis, sore throat, throat burning, chest tightness, hoarseness of voice. |
| FEF 25-75% | At day 1 of randomization, at 3 months of use of study drug | FEF 25-75% will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEF25-75% value will be converted into z-score by using GrowingLungs software. |
| Number of Exacerbations | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | Defined as having one major and 2 minor OR 2 major criteria irrespective of whether antibiotics are prescribed. Criteria for exacerbation: Major: (1) Wet cough over 72 hours, (2) Severe cough over 72 hours Minor: (1) Change in Sputum colour, (2) Chest pain, (3) SOB, (4) Haemoptysis, (5) + ve Chest signs At -1 month, we will look at the no of exacerbations in the past 1 year. Before the use of the study drug and after 3 months of use of the study drug, we will look at the no of exacerbations in the preceding 1 month and 3 months, respectively. |
Countries
Malaysia
Outcome results
None listed